Abstract CT213: ORIENT-16: Sintilimab plus XELOX vs placebo plus XELOX as 1st line treatment for unresectable advanced gastric and GEJ adenocarcinoma

医学 内科学 卡培他滨 肿瘤科 胃肠病学 化疗 养生 安慰剂 腺癌
作者
Jianming Xu,Yongshuai Jin,Ying Liu,Hui Hua Zhou,Yan Wang
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:79 (13_Supplement): CT213-CT213 被引量:8
标识
DOI:10.1158/1538-7445.am2019-ct213
摘要

Abstract Background: Gastric cancer is one of the most common malignant tumors worldwide, and the 2nd most common in China. The development of new agents for the treatment of advanced gastric cancer is stagnant. Immunotherapy which inhibits the programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) interaction is becoming a new option for treatment of late-stage gastric cancer (GC). Several trials suggest patients with PD-L1 positive expression (Combined Positive Score: CPS ≥ 1) population, especially CPS ≥ 10 population, are most likely to benefit from anti-PD-1 antibody treatment. Emerging data show encouraging efficacy signals of anti-PD-1 antibody in combination with chemotherapy in GC. Sintilimab, a highly selective, fully human, anti-PD-1 monoclonal antibody, was approved for relapsed or refractory Hodgkin Lymphoma in China in 2008. Based on the efficacy signals and the safety profile from a phase 1b trial of sintilimab plus XELOX regimen (oxaliplatin and capecitabine) as first line treatment for unresectable advanced gastric and GEJ adenocarcinoma, we aim to verify the therapeutic potential of sintilimab in combination with chemotherapy in patients with advanced GC/gastroesophageal junction (GEJ) cancer . Methods: The ORIENT-16 study (NCT: 03745170) is a randomized, double-blind, multi-center, phase III trial conducted in China to evaluate the efficacy and safety of sintilimab or placebo in combination with XELOX as first-line treatment in subjects with recurrent unresectable locally advanced or metastatic GC or GEJ adenocarcinoma. The study will enroll 650 patients. Patients will be randomly assigned in a 1:1 ratio to receive sintilimab every 3 weeks plus XELOX (capecitabine, 1000mg/m2 orally twice daily for 14 days followed by 7 days off; oxaliplatin, 130mg/m2 intravenously on day1 every 3 weeks) or placebo plus XELOX for up to six cycles. Thereafter, the patients will receive maintenance therapy with sintilimab every 3 weeks plus capecitabine (1000mg/m2 orally twice daily for 14 days followed by 7 days off) or placebo plus capecitabine every 3 weeks. Sintilimab will be dosed according to the subject’s bodyweight ( < 60kg, 3mg/kg; ≥ 60kg, 200mg). Stratification factors are ECOG Performance status (0 or 1), liver metastasis (yes or no) and PD-L1 expression score in tumor cells and immune cells (DAKO 22C3: CPS < 10 or ≥ 10). Major eligibility criteria include age between 18 and 75 years; newly diagnosed, recurrent unresectable locally advanced or metastatic G or GEJ adenocarcinoma; at least one evaluable tumor lesion according to RECIST v1.1 criteria; and patients must have fresh tumor tissue or archival tumor tissue for PD-L1 assessment from within 6 months of entrance. Patients with known HER2 positive G or GEJ cancer are excluded. Treatment will be discontinued for disease progression, unacceptable toxicity, patient / physician decision to withdraw or after 24-months of treatment. The primary endpoint is median overall survival assessed in both entire population and in PD-L1 positive (CPS ≥ 10) population of patients. Secondary endpoints include progression free survival, objective response rate, disease control rate,duration of response and safety. Recruitment is currently ongoing in multiple sites in China. Citation Format: Jianming Xu, Yongshuai Jin, Ying Liu, Hui Zhou, Yan Wang. ORIENT-16: Sintilimab plus XELOX vs placebo plus XELOX as 1st line treatment for unresectable advanced gastric and GEJ adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT213.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
imchenyin发布了新的文献求助30
刚刚
NexusExplorer的应助被cmh采纳,获得10
刚刚
灰鸽子发布了新的文献求助10
刚刚
刚刚
刚刚
无极微光的应助被成就的初瑶采纳,获得20
刚刚
科研通AI6.4的应助被ZsJJkk采纳,获得10
1秒前
1秒前
存亿点好运完成签到,获得积分10
1秒前
Meixiaoning完成签到 ,获得积分20
1秒前
罗龙生发布了新的文献求助10
1秒前
烟花的应助被铁锤牛马版采纳,获得10
1秒前
victor1995888完成签到,获得积分10
1秒前
yk发布了新的文献求助10
2秒前
2秒前
SamYang发布了新的文献求助10
2秒前
2秒前
2秒前
大模型的应助被曾经的康乃馨采纳,获得10
2秒前
霸气林完成签到,获得积分10
2秒前
超帅凡阳完成签到,获得积分20
3秒前
慕夏晚吹风完成签到 ,获得积分10
3秒前
香蕉黑米发布了新的文献求助10
3秒前
艾妮吗完成签到,获得积分10
4秒前
4秒前
sxxx完成签到,获得积分10
4秒前
hvtu发布了新的文献求助10
4秒前
阿飞发布了新的文献求助10
4秒前
丘比特的应助被肖望采纳,获得10
4秒前
DXXP完成签到,获得积分10
4秒前
彩虹糖完成签到,获得积分10
4秒前
轻松柏柳完成签到 ,获得积分10
5秒前
科研通AI6.3的应助被撝谦采纳,获得10
5秒前
Cedric完成签到,获得积分10
5秒前
袁志阳完成签到,获得积分10
5秒前
6秒前
6秒前
超帅凡阳发布了新的文献求助10
6秒前
未了发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253